Select Transactions
|
| Acquisition of |
|
|
$225 million
September 2020
|
|
| Majority recap by |
|
|
$125 million
April 2019
|
|
| Sale of stock and conditional sale to |
|
|
$215 million + CVRs
February 2019
|
|
| Acquisition of generics business of |
|
|
$1.05 billion
June 2017
|
Torreya is a leading strategic M&A advisor to global life sciences companies. MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales. MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations. MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals. MORE
The Pharma 1000
Top Global Pharmaceutical Company Report
September 2020
Torreya report provides a snapshot of the global pharmaceutical industry in September 2020 and compares it to the industry in 2015.
Click Here for Report Executive Summary | Full Report (PDF 38.3MB) | Slide Overview (PDF 6.2MB)